Resources from the same session
Welcome and introduction
Presenter: Joyce O'Shaughnessy
Session: ESMO Colloquium supported by Eli Lilly and Company - Hormone-receptor (+), HER2 (-) advanced breast cancer: The biology and treatment landscape post-progression after CDK4/6 inhibition
Resources:
Webcast
Biological insights in the endocrine and CDK4/6 pathways of cellular signal transduction and mechanisms of primary/acquired resistance in HR(+)/HER2(-) breast cancer
Presenter: Elgene Lim
Session: ESMO Colloquium supported by Eli Lilly and Company - Hormone-receptor (+), HER2 (-) advanced breast cancer: The biology and treatment landscape post-progression after CDK4/6 inhibition
Resources:
Slides
Webcast
Presentation of a clinical case: State of the art management of patients with HR(+)/HER2(-) advanced breast cancer progressing after aromatase inhibitor+CDK4/6-inhibitor therapy
Presenter: Cristina Saura Manich
Session: ESMO Colloquium supported by Eli Lilly and Company - Hormone-receptor (+), HER2 (-) advanced breast cancer: The biology and treatment landscape post-progression after CDK4/6 inhibition
Resources:
Slides
Webcast
A glimpse of the future: Ongoing research on novel therapeutics for advanced breast cancer patients post-progression on endocrine+CDK4/6-inhibition
Presenter: Joyce O'Shaughnessy
Session: ESMO Colloquium supported by Eli Lilly and Company - Hormone-receptor (+), HER2 (-) advanced breast cancer: The biology and treatment landscape post-progression after CDK4/6 inhibition
Resources:
Slides
Webcast
Q&A and discussion
Session: ESMO Colloquium supported by Eli Lilly and Company - Hormone-receptor (+), HER2 (-) advanced breast cancer: The biology and treatment landscape post-progression after CDK4/6 inhibition
Resources:
Webcast
Concluding remarks
Presenter: Cristina Saura Manich
Session: ESMO Colloquium supported by Eli Lilly and Company - Hormone-receptor (+), HER2 (-) advanced breast cancer: The biology and treatment landscape post-progression after CDK4/6 inhibition
Resources:
Webcast